TOVX — Theriva Biologics Share Price
0.000.00%
Last trade - 00:00- $4.08m
- -$13.96m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.12 | ||
| Price to Tang. Book | 0.15 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -50.67% | ||
| Return on Equity | -44.95% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment. SYN-004 (ribaxamase) is designed to degrade certain commonly used intravenous beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage. SYN-020 is a recombinant oral formulation of the enzyme intestinal alkaline phosphatase produced under current good manufacturing practice conditions and intended to treat both local GI and systemic diseases. Its research programs include VCN-11 Albumin Shield Technology and SYN-006, SYN-007, other oncolytic virus.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- December 23rd, 2008
- Public Since
- February 12th, 1993
- No. of Shareholders
- 50
- No. of Employees
- 21
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 17,277,371
- Address
- 9605 Medical Center Drive, Suite 270, ROCKVILLE, 20850
- Web
- https://therivabio.com/
- Phone
- +1 7343327800
- Auditors
- BDO USA, LLP
Upcoming Events for TOVX
Theriva Biologics Inc Annual Shareholders Meeting
Q3 2024 Theriva Biologics Inc Earnings Release
Similar to TOVX
Actinium Pharmaceuticals
NYSE MKT
Aeon Biopharma
NYSE MKT
AIM ImmunoTech
NYSE MKT
Armata Pharmaceuticals
NYSE MKT
Azitra
NYSE MKT
FAQ
What is the Theriva Biologics share price?
As of Today at 23:44 UTC, shares in Theriva Biologics are trading at $0.24. This share price information is delayed by 15 minutes.
How has the Theriva Biologics share price performed this year?
Shares in Theriva Biologics last closed at $0.24 and the price had moved by -63.66% over the past 365 days. In terms of relative price strength the Theriva Biologics share price has underperformed the S&P500 Index by -71.08% over the past year.
What are the analyst and broker recommendations for Theriva Biologics?
The overall consensus recommendation for Theriva Biologics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Theriva Biologics dividend yield?
Theriva Biologics does not currently pay a dividend.
Does Theriva Biologics pay a dividend?
Theriva Biologics does not currently pay a dividend.
When does Theriva Biologics next pay dividends?
Theriva Biologics does not currently pay a dividend.
How do I buy Theriva Biologics shares?
To buy shares in Theriva Biologics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Theriva Biologics?
As of the previous close price of $0.24, shares in Theriva Biologics had a market capitalisation of $4.15m.
Where are Theriva Biologics shares listed?
Here are the trading details for Theriva Biologics:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: TOVX
What kind of share is Theriva Biologics?
Based on an overall assessment of its quality, value and momentum Theriva Biologics is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Theriva Biologics share price forecast for 2024?
The analyst consensus target price for shares in Theriva Biologics is $4.50. That is 1775% above the last closing price of $0.24.
Analysts covering Theriva Biologics currently have a consensus Earnings Per Share (EPS) forecast of -$1.20 for the next financial year.
What is the trend in the Theriva Biologics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Theriva Biologics. Over the past six months, its share price has underperformed the S&P500 Index by -52.07%.
As of the last closing price of $0.24, shares in Theriva Biologics were trading -46.6% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Theriva Biologics PE Ratio?
The Theriva Biologics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.24.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Theriva Biologics?
Theriva Biologics' management team is headed by:
- Jeffrey Kraws - NEC
- Steven Shallcross - CEO
- John Monahan - IND
- Jeffrey Wolf - IND